Uveitis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
Uveitis, a significant cause of blindness in the United States, is experiencing an increasing prevalence. This has led to substantial growth prospects for the global uveitis treatment market. The market has shown consistent expansion, with projections indicating strong growth during the forecast period of 2024 to 2031.
North America and Europe Lead in Clinical Trials
Clinical trials for uveitis treatment are actively underway in North America and Europe. The United Kingdom and France are at the forefront of clinical research in Europe, while countries such as India, Singapore, South Korea, and China are gaining momentum due to the high prevalence of uveitis among their populations.
North America: The Largest Regional Market
North America currently dominates the global uveitis treatment market, representing more than 30% of the total market. It is expected to maintain its leading position, expanding at a CAGR of 7.3% over the forecast period. By the end of 2024, the North American market is projected to exceed US$ 270 million, offering substantial opportunities for investors.
The United States is poised to drive revenue growth in the North American uveitis treatment market, with market revenue expected to grow 1.8 times by the end of 2024 compared to 2016.
Canada is also set to make significant contributions to the market's expansion, with projections indicating a market valuation in excess of US$ 50 million by 2024, growing at a CAGR of 6.3% during the forecast period.
APAC Region Emerges as a Lucrative Market
The Asia-Pacific (APAC) region is expected to see impressive growth in the uveitis treatment market, expanding at a CAGR of 6.7% and nearing a market valuation of US$ 194 million by 2024. Japan is the largest market within APAC, representing more than 25% of the total market and expected to expand at a CAGR of 6.8% over the forecast period.
China stands out as the fastest-growing market in the region, projected to exceed US$ 40 million over the forecast period. Meanwhile, revenue from the Indian market is anticipated to grow 1.7 times by 2024.
Innovations in Uveitis Treatment
The uveitis treatment market is witnessing substantial innovation, with leading market players enhancing their product portfolios by introducing new drugs. Notably, DE-109 (phase III), manufactured by Santen Pharmaceutical Co. Ltd. (sirolimus), is in the pipeline for uveitis treatment and has received orphan drug designation from U.S. and European regulatory authorities for treating non-infectious posterior uveitis.
However, the manufacturing of sterile formulations poses significant challenges, leading companies to align with Good Manufacturing Practices (GMP) and regulatory guidelines to ensure product quality.
The global uveitis treatment market is set for exciting growth opportunities, with North America and the APAC regions emerging as the most attractive regions for investors. As new therapies continue to develop, the market is expected to address the growing prevalence of uveitis and improve the quality of life for affected individuals.
Global Uveitis Treatment Market: Segmentation
By Treatment Type
• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Antibiotics
• Antivirals
• Antifungal
• Analgesics
By Disease Type
• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis
By Cause
• Infectious Uveitis
• Non-infectious Uveitis
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• MEA
Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.